Profile
Alan Glicklich worked as Vice President-Clinical Affairs at Savient Pharmaceuticals, Inc. in 2013, Vice President-Clinical Development at Arena Pharmaceuticals, Inc. from 2014 to 2015, and Chief Medical Officer at Bird Rock Bio, Inc. from 2015 to 2020.
He also held the position of Vice President-Clinical Affairs at Veloxis Pharmaceuticals, Inc. and Chief Medical Officer at Chinook Therapeutics, Inc. from 2020 to 2022.
Glicklich earned an MBA from Emory University, an undergraduate degree from The University of Chicago, and a doctorate from the University of Wisconsin.
Former positions of Alan Glicklich
| Companies | Position | End |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2022-02-10 |
Bird Rock Bio, Inc.
 Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | 2020-04-30 |
| ARENA PHARMACEUTICALS | Corporate Officer/Principal | 2015-08-31 |
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 2013-09-30 |
Veloxis Pharmaceuticals, Inc.
 Veloxis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Asahi Kasei Corp., Veloxis Pharmaceuticals, Inc. manufactures pharmaceuticals for kidney transplant patients. The private company is based in Edison, NJ. | Corporate Officer/Principal | - |
Training of Alan Glicklich
| Emory University | Masters Business Admin |
| The University of Chicago | Undergraduate Degree |
| University of Wisconsin | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protein-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in Park City, UT. | Health Technology |
Bird Rock Bio, Inc.
Bird Rock Bio, Inc. BiotechnologyHealth Technology Bird Rock Bio, Inc. develops protein therapeutics. It focuses on the discovery and development of novel antibodies with upsized potential that represent to antibody therapeutics. The company was founded by Richard J. Ulevitch, Phyllis Ellen Whiteley and Katherine S. Bowdish in 2007 and is headquartered in La Jolla, CA. | Health Technology |
Veloxis Pharmaceuticals, Inc.
Veloxis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Asahi Kasei Corp., Veloxis Pharmaceuticals, Inc. manufactures pharmaceuticals for kidney transplant patients. The private company is based in Edison, NJ. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Alan Glicklich
